Screening of flavonoids for effective osteoclastogenesis suppression

Analytical Biochemistry

Volumn 433, Issue 1, 2013, Pages 48-55

  Wu, Yu Wei ^a,b   Chen, Shih Ching ^c   Lai, Wen Fu Thomas ^a,c   Chen, Yen Chou ^a   Tsai, Yu Hui ^a,b,c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bone resorption; Flavonoids; Osteoclast; Osteoporosis; Tartrate resistant acid phosphatase

Indexed keywords

DISEASES; FLAVONOIDS; PHOSPHATASES;

BONE RESORPTION; INHIBITORY CONCENTRATION; OSTEOCLAST; OSTEOCLAST FORMATION; OSTEOCLASTOGENESIS; OSTEOPOROSIS; RECEPTOR ACTIVATOR; TARTRATE-RESISTANT ACID PHOSPHATASE;

BONE;

6 HYDROXYFLAVONE; 7 HYDROXYFLAVONE; 7 METHOXYFLAVONE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; AURANTIIN; BAICALEIN; BAICALIN; DAIDZEIN; FLAVONE; FLAVONOID; GENISTEIN; HESPERETIN; HESPERIDIN; KAEMPFEROL; METHOXYFLAVONE; MORIN; MYRICETIN; NARINGENIN; OSTEOCLAST DIFFERENTIATION FACTOR; QUERCETIN; RUTOSIDE; TAXIFOLIN; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE TURNOVER; CONTROLLED STUDY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; IC 50; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL;

EID: 84870165859     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2012.10.008     Document Type: Article

References (26)

1. M. Gass, and B. Dawson-Hughes Preventing osteoporosis-related fractures: an overview Am. J. Med. 119 2006 S3 S11
2. A. Howell, and G.D. Evans Hormone replacement therapy and breast cancer Recent Results Cancer Res. 188 2011 115 124
3. B. Zhou, Q. Sun, R. Cong, H. Gu, N. Tang, L. Yang, and B. Wang Hormone replacement therapy and ovarian cancer risk: a meta-analysis Gynecol. Oncol. 108 2008 641 651
4. Z.C. Dang, and C. Lowik Dose-dependent effects of phytoestrogens on bone Trends Endocrinol. Metab. 16 2005 207 213
5. R.C. Poulsen, and M.C. Kruger Soy phytoestrogens: impact on postmenopausal bone loss and mechanisms of action Nutr. Rev. 66 2008 359 374
6. E. Middleton, C. Kandaswami, and T.C. Theoharides The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer Pharmacol. Rev. 52 2000 673 751
7. J.A. Ross, and C.M. Kasum Dietary flavonoids: bioavailability, metabolic effects, and safety Annu. Rev. Nutr. 22 2002 19 34
8. L.H. Cazarolli, L. Zanatta, E.H. Alberton, M.S. Figueiredo, P. Folador, R.G. Damazio, M.G. Pizzolatti, and F.R. Silva Flavonoids: prospective drug candidates Mini Rev. Med. Chem. 8 2008 1429 1440
9. C.G. Di, N. Mascolo, A.A. Izzo, and F. Capasso Flavonoids: old and new aspects of a class of natural therapeutic drugs Life Sci. 65 1999 337 353
10. Y. Imai, S. Tsukahara, S. Asada, and Y. Sugimoto Phytoestrogens/ flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance Cancer Res. 64 2004 4346 4352
11. P. Garcia, V.L.J. Robinson, C.W. Borysenko, T. Lehmann, S.E. Kalla, and H.C. Blair Negative regulation of RANKL-induced osteoclastic differentiation in RAW264.7 cells by estrogen and phytoestrogens J. Biol. Chem. 280 2005 13720 13727
12. S.L. Teitelbaum Bone resorption by osteoclasts Science 289 2000 1504 1508
13. W.J. Boyle, W.S. Simonet, and D.L. Lacey Osteoclast differentiation and activation Nature 423 2003 337 342
14. J.M. Halleen, S.L. Tiitinen, H. Ylipahkala, K.M. Fagerlund, and H.K. Vaananen Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption Clin. Lab. 52 2006 499 509
15. J.M. Halleen, H. Ylipahkala, S.L. Alatalo, A.J. Janckila, J.E. Heikkinen, H. Suominen, S. Cheng, and H.K. Vaananen Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density Calcif. Tissue Int. 71 2002 20 25
16. L. Scarnecchia, S. Minisola, M.T. Pacitti, V. Carnevale, E. Romagnoli, R. Rosso, and G.F. Mazzuoli Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover Scand. J. Clin. Lab. Invest. 51 1991 517 524
17. M.N. Dugard, C.A. Sharp, S.F. Evans, J.H. Williams, M.W. Davie, and M.J. Marshall A bio-assay for effectors of osteoclast differentiation in serum from patients with bone disease Clin. Chim. Acta 356 2005 154 163
18. S.L. Alatalo, J.M. Halleen, T.A. Hentunen, J. Monkkonen, and H.K. Vaananen Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium Clin. Chem. 46 2000 1751 1754
19. B. Kirstein, T.J. Chambers, and K. Fuller Secretion of tartrate-resistant acid phosphatase by osteoclasts correlates with resorptive behavior J. Cell. Biochem. 98 2006 1085 1094
20. T.H. Kim, J.W. Jung, B.G. Ha, J.M. Hong, E.K. Park, H.J. Kim, and S.Y. Kim The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss J. Nutr. Biochem. 22 2011 8 15
21. N. Takahashi, N. Udagawa, S. Tanaka, and T. Suda Generating murine osteoclasts from bone marrow M.H. Helfrich, S.H. Ralston, Bone Research Protocols 2003 Humana Press Totowa, NJ 129 144
22. J. Weischenfeldt, and B. Porse Bone marrow-derived macrophages (BMM): isolation and applications Cold Spring Harbor Protoc. 2008 10.1101/pdb.prot5080
23. S.Y. Wang, H. Castro-Malaspina, and M.A. Moore Long-term culture of human bone marrow macrophages: macrophage development is associated with the production of granulomonopoietic enhancing activity (GM-EA) J. Immunol. 135 1985 1186 1193
24. A. Wattel, S. Kamel, C. Prouillet, J.P. Petit, F. Lorget, E. Offord, and M. Brazier Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1 J. Cell. Biochem. 92 2004 285 295
25. E.S. Ang, X. Yang, H. Chen, Q. Liu, M.H. Zheng, and J. Xu Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-kappaB and ERK activation FEBS Lett. 585 2011 2755 2762
26. L. Zhu, H. Wei, Y. Wu, S. Yang, L. Xiao, J. Zhang, and B. Peng Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo Int. J. Biochem. Cell Biol. 44 2012 1139 1152